Pall Corp

Pall — Q3 FY2012 Earnings Presentation

30 slides from Pall's earnings presentation, Jun 7, 2012

  1. Slide 1: Q3 FY 2012 Financial Results

    Q3 FY 2012 Financial Results June 7, 2012 Better Lives. Better Planet.SM Exhibit 99.2

  2. Slide 2: Forward-looking statements

    2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the third quarter are preliminary until the Company’s form 10-Q is filed with the Securities and Exchange Commission on or before June 11,

  3. Slide 3: Conference Call Replay Info

    3 • Toll-Free: 855-859-2056 • International: 404-537-3406 • Conference ID: 82873458 • Internet: www.pall.com/investor Conference Call Replay Info

  4. Slide 4: Agenda

    4 • Q3 Financial Performance • Impact of Blood Business Divestiture • Restructuring Update • Review of FY 2012 Outlook • Preview of FY 2013 Agenda All remarks in this presentation are on a “Continuing Operations” basis, which excludes the results of the Blood product line divestiture, unless indicat

  5. Slide 5: Overview of the Quarter

    5 • Enterprise system conversion drove sales shortfall in consumables in the Americas • Conversion also created orders fluctuation over the past 3-4 months as customers buffered stock • Softness in short-term book-to-ship activity due to 3rd quarter slowing of Laboratory demand • European economic i

  6. Slide 6: Pall Q3 FY 2012 YOY Sales Bridge

    6 Pall Q3 FY 2012 YOY Sales Bridge ($ in millions, sales changes exclude F/X) System product sales drove growth; Consumables sales negatively impacted ~3 points by enterprise system implementation ($ in millions) Q3 FY12 Bridge Percent Change Q3 FY11 Bridge Percent Change Q3 FY11 and Q3 FY10 Sales,

  7. Slide 7: Q3 FY 2012 Sales by Region

    7 $75 $125 $175 $225 $275 Q3 FY11 Q3 FY12 Q3 FY11 Q3 FY12 Q3 FY11 Q3 FY12 Americas $196 $185 $201 $204 Europe Asia $268 $258 Q3 FY 2012 Sales by Region ($ in millions, sales changes exclude F/X) Americas (-1.7%) • Supply chain interruption • Biopharm, Lab, Food & Bev and Aerospace markets most impac

  8. Slide 8: Life Sciences Sales

    8 Life Sciences Sales  In BioPharm, Pharmaceuticals consumables sales were up 9%  Biotech demand  Demand for new product lines: Octet® and BLitz™  Double-digit decline in Lab instrumentation sales on market weakness  Food & Beverage systems up $9M (or +71% LC); however, base sales declined 10%

  9. Slide 9: Industrial Sales

    9 Industrial Sales ($ in millions, discussion of sales changes exclude F/X) Q3 FY 2012 Q3 FY 2011 CHANGE CHANGE EXCL. F/X Process Technologies $214 $208 +2.7% +4.7% Aerospace $51 $51 (-0.5%) +1.0% Microelectronics $75 $82 (-7.8%) (-7.8%) Total Industrial $340 $341 (-0.3%) +1.2%  Sales in Process Te

  10. Slide 10: Pall Q3 FY 2012 Orders

    10 Pall Q3 FY 2012 Orders ($ in millions, orders changes exclude F/X) Underperformance in systems and a very strong Q3 FY11 comparable primarily drove the decline in orders ($ in millions) Q3 FY12 Bridge Percent Change Q3 FY11 Bridge Percent Change Q3 FY11 and Q3 FY10 Orders, Respectively $705 $610

  11. Slide 11: Q3 FY 2012 Orders by Region

    11 Q3 FY 2012 Orders by Region ($ in millions, orders changes exclude F/X) Europe: (-20%) • Tough comparable in BioPharm • Macro concerns • Systems down 60% Americas +5% • Solid performance in both consumables and systems • Medical increased 13% • BioPharm up ~23% • Commercial Aerospace up ~22% Asia

  12. Slide 12: Industrial Orders

    12 Industrial Orders ($ in millions, discussion of sales changes exclude F/X) Q3 FY 2012 Q3 FY 2011 CHANGE CHANGE EXCL. F/X Process Technologies $192 $230 (-16.6)% (-15.3)% Aerospace $52 $68 (-23.8)% (-22.9)% Microelectronics $78 $87 (-10.1)% (-10.1)% Total Industrial $322 $385 (-16.4%) (-15.5%)  C

  13. Slide 13: Life Sciences Orders

    13 Life Sciences Orders  BioPharm continues to perform well  Pharma consumables up ~10%  Demand for new product lines: Octet® and BLitz™  Systems down ~60%  Laboratory instrumentation down ~14%  Medical down in Europe partially offset by a 13% increase in the Americas  Food & Beverage was dow

  14. Slide 14: Impact of the Blood Divestiture

    14 Impact of the Blood Divestiture • Generated $57M in revenue and $0.09(1) in pro forma EPS in Q3 • FY 2012 Financial Expectations: – Revenue ~$230M – Operating profit ~$60M – Pro forma EPS ~$0.38 • Expect to receive $430M of cash proceeds upon closing in Q1 FY 2013, after-tax(2) • Capital allocati

  15. Slide 15: Segment Performance: Industrial

    15 $ in millions FY12 Actual FY11 Actual(a) Change Sales 340.0$ 341.1$ +1.2% LC Gross Profit 154.2$ 157.2$ Gross Margin 45.4% 46.1% (-70 bps) SG&A 107.5$ 102.9$ +4.5% % of Sales 31.6% 30.2% +140 bps R&D 7.3$ 7.1$ +1.7% % of Sales 2.1% 2.1% – Segment Profit 39.4$ 47.2$ (-16.5%) % of Sales 11.6% 13.8%

  16. Slide 16: Segment Performance: Life Sciences

    16 $ in millions FY12 Actual FY11 Actual(a) Change Sales 318.0$ 312.7$ +4.0 % LC Gross Profit 180.2$ 175.1$ Gross Margin 56.7% 56.0% +70 bps SG&A 91.3$ 84.0$ +8.7% % of Sales 28.7% 26.9% +180 bps R&D 13.5$ 12.2$ +11.1% % of Sales 4.2% 3.9% +30 bps Segment Profit 75.4$ 78.9$ (-4.4%) % of Sales 23.7%

  17. Slide 17: Analysis of Euro Risk

    17 Analysis of Euro (€) Risk • ~25% of Pall sales are denominated in Euro.~70 - 80% of the cost associated with these sales are GBP (60%) and USD (20%) denominated. • Impact to Gross Profit: • Q3 FY 2012 • Vs. BOY outlook ~(-$3.0) • Vs. Q3 FY 2011 ~(-$2.5) • Q4E FY 2012 • Vs. BOY outlook ~(-$3.5) •

  18. Slide 18: Financial Recap Q3 FY 2012 vs. Q3 FY 2011

    18 Financial Recap Q3 FY 2012 vs. Q3 FY 2011 $654 $658 $- $200 $400 $600 $800 FY2011 FY2012 Revenue 16.8% 15.0% 10.0% 15.0% 20.0% FY2011 FY2012 Operating Profit Margin $0.64 $0.61 $- $0.50 $1.00 FY2011 FY2012 Pro forma EPS 2.5% Growth Excluding F/X 180 bps contraction 4.7% Decline Pro forma EPS Brid

  19. Slide 19: Liquidity and Working Capital

    19 Liquidity and Working Capital (a) Days in Cash Conversion Cycle = Days Sales Outstanding plus Days Inventory Outstanding less Days Payable Outstanding. ($ in millions) Q3 YTD FY12 Q3 YTD FY11 Operating Cash Flow 326$ 281$ CapEx (127) (103) Free Cash Flow $199 178$ Other Significant Uses of Cash:

  20. Slide 20: Outlook

    20 Outlook • FY 2012 EPS of ~$3.10 for Total Pall; $2.72 on a continuing operations basis • FY 2013 Preliminary Discussion – Anticipate low single-digit revenue growth next year – Assume ~35% incremental margin (before structural cost action and FX headwind at current rates) – Targeting $100M of str

  21. Slide 21: Pall Corporation

    Pall Corporation

  22. Slide 22: Reconciliation of Non-GAAP Financial Measures

    22 Appendix: Reconciliation of Non-GAAP Financial Measures Third Quarter Quarter Diluted EPS as reported 0.60$ 0.52$ Tax Adjustments - 0.07 ROTC, after pro forma tax effect 0.01 0.05 Pro forma diluted EPS 0.61$ 0.64$ Q3 FY12 Q3 FY11 Nine Months Diluted EPS as reported 1.74$ 1.60$ Tax Adjustments - 0

  23. Slide 23: Reconciliation of Non-GAAP Financial Measures

    23 Appendix: Reconciliation of Non-GAAP Financial Measures (amounts in millions) Q3 FY12 Q3 FY12 Estimated Impact of FX Q3 FY12 Estimate Excluding FX Q3 FY11 % Change Excluding FX Sales: BioPharmaceuticals 201.7$ (4.3)$ 206.0$ 197.2$ 4.4% Medical 49.7 (1.2) 50.9 51.7 -1.5% Food & Beverage 66.6 (1.8)

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures

    24 Appendix: Reconciliation of Non-GAAP Financial Measures (amounts in millions) Q3 FY12 Q3 FY12 Estimated Impact of FX Q3 FY12 Estimate Excluding FX Q3 FY11 % Change Excluding FX Sales: Americas 95.5$ (0.7)$ 96.2$ 88.2$ 9.1% Europe 154.5 (7.1) 161.6 164.7 -1.9% Asia 68.0 0.6 67.4 59.8 12.6% Life Sc

  25. Slide 25: Reconciliation of Non-GAAP Financial Measures

    25 Appendix: Reconciliation of Non-GAAP Financial Measures (amounts in millions) 9 Months FY12 9 Months FY12 Estimated Impact of FX 9 Months FY12 Estimate Excluding FX 9 Months FY11 % Change Excluding FX Sales: BioPharmaceuticals 599.3$ 4.7$ 594.6$ 538.1$ 10.5% Medical 143.7 0.8 142.9 146.6 -2.5% Fo

  26. Slide 26: Reconciliation of Non-GAAP Financial Measures

    26 Appendix: Reconciliation of Non-GAAP Financial Measures (amounts in millions) 9 Months FY12 9 Months FY12 Estimated Impact of FX 9 Months FY12 Estimate Excluding FX 9 Months FY11 % Change Excluding FX Sales: Americas 270.3$ (1.0)$ 271.3$ 250.5$ 8.3% Europe 460.4 0.8 459.6 436.6 5.3% Asia 188.3 6.

  27. Slide 27: Reconciliation of Non-GAAP Financial Measures

    27 Appendix: Reconciliation of Non-GAAP Financial Measures (amounts in millions) Q3 FY12 Q3 FY12 Estimated Impact of FX Q3 FY12 Estimate Excluding FX Q3 FY11 % Change Excluding FX Orders: BioPharmaceuticals 199.3$ (4.3)$ 203.6$ 202.1$ 0.8% Medical 52.5 (1.1) 53.6 54.5 -1.7% Food & Beverage 59.0 (1.4

  28. Slide 28: Reconciliation of Non-GAAP Financial Measures: Operating Profit

    28 Appendix: Reconciliation of Non-GAAP Financial Measures Operating Profit ($ in millions) Q3 FY12 Q3 FY11 Life Sciences segment profit 75.4$ 78.9$ Industrial segment profit 39.4 47.2 Total segment profit 114.8 126.1 General corporate expenses (16.4) (16.5) Operating profit 98.4 109.6 % of Sales 15

  29. Slide 29: Reconciliation of Non-GAAP Financial Measures: Operating Profit

    29 Appendix: Reconciliation of Non-GAAP Financial Measures Operating Profit ($ in millions) 9 Months FY12 9 Months FY11 Life Sciences segment profit 233.2$ 213.7$ Industrial segment profit 131.2 134.3 Total segment profit 364.4 348.0 General corporate expenses (49.8) (45.8) Operating profit 314.6 30

  30. Slide 30: Pall Corporation

    Pall Corporation ENABLING A GREENER FUTURE. www.pall.com/green

Pall — Q3 FY2012 Earnings Presentation on 6ix